Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Blis Technologies Signs Korean Deal

News Release 26 November 2002

BLIS TECHNOLOGIES SIGNS KOREAN DEAL

Listed Biotechnology company BLIS Technologies has signed a commercial arrangement to have its BLIS K12 Throat Guard sold in Korea.

BLIS Technologies created a world first earlier this year when it began selling throat guard lozenges that use beneficial and natural occurring bacteria to help maintain throat health.

BLIS Technologies initial sales focus has been on the New Zealand and European markets but its latest venture with Australian based company Astra Grace, which trades under the name of Lifecare Natural in Korea, is the company’s first foray into Asia.

BLIS Technologies chief executive Kelvin Moffatt said the Korean agreement was a further opportunity to reinforce BLIS Technologies’ mission of becoming a highly successful international company with a range of research based high quality, biological products.

“This is our first push into the Asian market. With a population of 50 million, Korea is obviously an exciting market. We also see a priority in establishing a presence in Japan and Taiwan. Then there is the massive Chinese market as well, “Mr Moffatt said.

The Asian market generally is known for the willingness of its people to use health products to improve their personal health and well being,” Mr Moffatt said.

Mr Moffatt said BLIS Technologies would essentially be providing finished product as Lifecare Natural was contracted to provide registration, marketing, promotion and distribution in Korea.

BLIS K12 Throat Guard was only the beginning of a continuing rollout, which would see a host of products launched internationally over the next few years.

“Over the last year our research team have worked very hard on development of a formulation suitable for hot Asian and Mediterranean climates, and the success they have achieved now gives us access to these markets and which can be applied across our future pipeline as well. This in house expertise on formulation of these types of products, offers further competitive protection to our range, in addition to our strong patent position”

BLIS Technologies second product BLIS Bio RESTORE will be on the market in early 2003 with a tooth decay preventative also in the pipeline.

BLIS Bio RESTORE works by restoring and maintaining beneficial oral and intestinal bacteria following a course of antibiotics. BLIS Technologies chief executive Kelvin Moffatt said when antibiotics are prescribed, undesirable bugs as well as good bacteria necessary for everyday well being, are killed. When beneficial bacteria are depleted following a course of antibiotics, people are prone to antibiotic side effects. Using BLIS Bio RESTORE can help maintain health after antibiotic use by restoring beneficial bacteria and helping support the body’s natural defences against the overgrowth of undesirable micro-organisms

ENDS


ABOUT BLIS TECHNOLOGIES
BLIS Technologies was formed in June 2000 to pursue the commercialisation of BLIS (bacteriocin-like inhibitory substances). In an unusual move for a new company, BLIS Technologies was listed on the New Zealand Stock Exchange less than a year after it was set up. This encouraged sound investment and the company raised enough funding to support its research and development programme for four years. The company has its own research laboratory based at Otago University’s Centre for Innovation. The research team comprises among others: the University of Otago Professor of Microbiology, Professor John Tagg; BLIS Technologies’ Director of Science, Dr Chris Chilcott; and Dr Cheung-Tak Hung from Zenith Technology Corporation Limited.


Issued on behalf of BLIS Technologies by Sorensen Group.

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Half Full: Fonterra Raises Forecast Payout As Global Supply Shrinks

Fonterra Cooperative Group, the dairy processor which will announce annual earnings tomorrow, hiked its forecast payout to farmers by 50 cents per kilogram of milk solids as global supply continues to decline, helping prop up dairy prices. More>>

ALSO:

Results:

Meat Trade: Silver Fern Farms Gets Green Light For Shanghai Maling Deal

The government has given the green light for China's Shanghai Maling Aquarius to acquire half of Silver Fern Farms, New Zealand's biggest meat company, with ministers satisfied it will deliver "substantial and identifiable benefit". More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news